UthPeak™ NMNH: 5 Years Younger Clinically Proven

Overview


Effepharm

NMNH, the reduced form of NMN, is a potent NAD+ precursor.

UthPeak™ reduced NMN (NMNH), the world’s first Self-GRAS approved, US patent-pending reduced NMN, completed the first, largest and longest Phase I clinical trial, demonstrating a remarkable 5-year age reversal validated by UCLA’s epigenetic study in “Aging” the global golden standard for measuring biological age.

Highlights of the clinical trial are:

● NAD+ Levels: Increased by 3 times

● Biological Age: Reduced by an average of 5 years

● Energy Levels: Enhanced by 35%

● Emotional Health: Improved by 31%

Contact us for more clinical study details.

This content is paid by Effepharm Ltd, and any views and opinions expressed do not necessarily reflect those of NutraIngredients.com

Download Now


Latest Content

Related Resources

The Only & 1st NMN Got Novel Food EFSA Positive Safety Opinion

The Only & 1st NMN Got Novel Food EFSA Positive Safety Opinion

Paid for by Effepharm Ltd

White Paper

On 11th May 2026, EFSA officially published a positive scientific opinion on EffePharm’s β-NMN as a novel food. This is the first-ever EU official safety endorsement for NMN. UTHEVER® is the 1st NMN ingredient brand to receive EFSA’s positive opinion.

Uthever® NMN: Novel Food Approval Nearing Final Stage

Uthever® NMN: Novel Food Approval Nearing Final Stage

Paid for by Effepharm Ltd

White Paper

One Step Away from EU Market Compliance for NMN. The official positive opinion of Novel Food is expected to be published shortly, which means Uthever® NMN will be the first compliant ingredient.

Supplier Info Centre

Effepharm-Ltd.jpg

For more product information visit Effepharm Ltd.